HSP 78 Inhibitors

HSP 78 Inhibitors are compounds that interact with the HSP70 family of proteins, to which HSP 78 belongs, and influence their function. Compounds like 17-AAG and Geldanamycin are known to inhibit HSP90, a closely related chaperone protein. The inhibition of HSP90 can lead to the destabilization and degradation of its client proteins. If HSP 78 functions in concert with HSP90 or is a client protein, these inhibitors would decrease its functional activity. Similarly, Quercetin and VER-155008, which bind to the ATPase domain of HSP70 proteins, could impair the ATPase activity of HSP 78, leading to reduced chaperone function.

Compounds such as Radicicol and Novobiocin also target HSP90, but by binding different domains-the ATPase domain for Radicicol and the C-terminal domain for Novobiocin. This binding can affect the stability and function of client proteins, including potentially HSP 78. Triptolide and Silibinin may lead to decreased expression of HSP70 family proteins, which could result in a reduction of HSP 78 levels and its associated activity. EGCG and Deoxyspergualin interact with HSP70 proteins by binding to their substrate-binding domains, potentially inhibiting HSP 78 by altering its ability to interact with substrates. MKT-077, a mitochondrial-targeted compound, inhibits mitochondrial HSP70 family proteins, which could lead to a decrease in HSP 78 activity if HSP 78 is localized to mitochondria.